Neuphoria Therapeutics Inc. (NEUP) compared with its closest peers (CLRB, TXMD, ABVC, MRKR, ALLR): P/E 7.9 vs industry 17.0. Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Cellectar Biosciences, Inc. (CLRB) | $24.39M | -0.3 |
| TherapeuticsMD, Inc. (TXMD) | $23.79M | 47.9 |
| ABVC BioPharma, Inc. (ABVC) | $23.38M | -5.4 |
| Marker Therapeutics, Inc. (MRKR) | $23.09M | -1.8 |
| Allarity Therapeutics, Inc. (ALLR) | $22.28M | -1.4 |
| Biofrontera Inc. (BFRI) | $21.91M | -0.7 |
| Cocrystal Pharma, Inc. (COCP) | $21.86M | -1.2 |
| Celularity Inc. (CELU) | $20.29M | -0.3 |
| Cyclerion Therapeutics, Inc. (CYCN) | $18.21M | -1.1 |
| Tempest Therapeutics, Inc. (TPST) | $17.10M | -0.4 |
| Stock P/E | 7.9 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
| vs Sector | -63.7% |
| vs Industry | -53.6% |
NEUP overview · NEUP earnings · NEUP financials · NEUP KPIs · NEUP investor relations · NEUP ownership · NEUP filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.